Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancer
8th September 2024 Uncategorised 0Akeso, Summit’s PD-1 bispecific crushes Merck’s Keytruda in study, signaling potential new standard in lung cancer aliu Sun, 09/08/2024 – 07:43 More: Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancer Source: fierce
read more